Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition

) Overview Vivos Q3 2025 revenue rises 76% yr/yr, driven by SCN acquisition Company’s gross margin declines to 58% from 60% due to pricing discounts Operating expenses increase 74% due to SCN acquisition-related costs Outlook Vivos expects near-term expenses to rise due to investments in SCN operations Company plans to expand sleep center model beyond Las Vegas Vivos anticipates seeing patients at new Michigan location by December Result Drivers SCN ACQUISITION IMPACT - Vivos attributes 78% sequential revenue growth to the acquisition of The Sleep Center of Nevada STRATEGIC PIVOT - Co’s shift from dental distribution to direct medical affiliations drives revenue increase Key Details Metric Beat/Mis Actual Consensu s s Estimate Q3 Net -$5.4 Income mln Q3 Gross $3.94 Profit mln Q3 -$4.73 Operatin mln g Income Analyst Coverage The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell” The average consensus recommendation for the medical equipment, supplies & distribution peer group is “buy” Wall Street’s median 12-month price target for Vivos Therapeutics Inc is $6.50, about 62% above its November 18 closing price of $2.47 Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)